Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestor.lilly.com
Eli Lilly and Company News Releases
Get the latest updates from Eli Lilly and Company News Releases directly as they happen.
Follow now 268 followers
Latest posts
Last updated 3 days ago
NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery In the Age of AI
3 days ago
News Summary: NVIDIA and Lilly bring together a world-leading, multidisciplinary team of...
Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight
7 days ago
At 36 weeks, the TOGETHER-PsA study met its primary endpoint of 50%...
Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases
8 days ago
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies...
Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial
29 days ago
In ATTAIN-MAINTAIN, orforglipron achieved the primary and all key secondary endpoints for...
Lilly to participate in J.P. Morgan Healthcare Conference
about 1 month ago
INDIANAPOLIS , Dec. 16, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE...
Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer
about 1 month ago
As monotherapy, imlunestrant demonstrated an 11.4-month numeric improvement in median OS versus...
Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial
about 1 month ago
In TRIUMPH-4, participants with obesity and knee osteoarthritis taking retatrutide 12 mg...
Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama
about 1 month ago
Huntsville site will focus on domestic production of small molecule synthetic and...
Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition
about 1 month ago
INDIANAPOLIS , Dec. 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE...
Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL
about 1 month ago
The risk reduction observed in BRUIN CLL-313 is among the most compelling...
Lilly declares first-quarter 2026 dividend
about 1 month ago
INDIANAPOLIS , Dec. 8, 2025 /PRNewswire/ -- The board of directors of...
Carolyn Bertozzi returns to Lilly board of directors
about 1 month ago
INDIANAPOLIS , Dec. 8, 2025 /PRNewswire/ -- The board of directors of...